サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028

生物製剤原薬(API)製造サービス世界の業界と市場予測2018−2028

レポート概要

生物製剤原薬(API)製造市場は予測期間の前半に9.0%のCAGRが見込まれます。2017年には生物製剤API製造受託産業の中で哺乳動物細胞培養システムのサブマーケットが最大となっています。

この209ページのレポートの内容:

・ 2018-2028年における主要サブマーケットを定性的、定量的に分析します。
これらのサブマーケットの売上と伸び率を予測します:
・ 哺乳動物の細胞培養
・ 微生物発酵
・ その他の発現プラットフォーム

2018-2028年における主要な生物製剤API製造受託市場の定性的、定量的分析を示します。
これらのセグメント別に売上を予測します:
・ モノクローナル抗体(mAb)療法
・ ワクチン
・ インスリン療法
・ インターフェロン療法
・ 成長ホルモン

2018−2028年における国別予測:
・ EU主要5か国(英国、ドイツ、フランス、イタリア、スペイン)を含む
・ 米国
・ 日本
・ スイス
・ BRIC (ブラジル、ロシア、インド、中国)、韓国、シンガポールなどの新興市場

・ 医薬品産業にバイテクAPI製造受託サービスを提供している主要なグローバルおよび国内企業のプロフィール。各企業について、現在提供しているサービス、最近の開発品、将来展望について深く掘り下げます。
個々に取り上げる主なCMO:
・ Boehringer Ingelheim BioXcellence
・ Celltrion
・ DSM Biologics
・ Lonza
・ Samsung BioLogics
・ Cytovance Biologics
・ Fujifilm Diosynth Biotechnologies
・ Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

レポート詳細

目次

1. Report Overview
1.1 Contract Biological Drug API Manufacturing: World Market Review 2017
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Report For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Some Associated Reports
1.7 About Visiongain

2. Introduction to Biological drug API Manufacturing Services
2.1 What are Biological drug API Manufacturing Services?
2.1.1 Producing Biological drug API: An Overview of the Manufacturing Process
2.1.2 Defining the Biological drug API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biological drug API
2.3 Outsourcing: A Common Trend in Biological drug API Manufacturing Services
2.4 Future Trends for the Biological drug API Manufacturing Services Market

3. Biological drug API Manufacturing Services: World Market Outlook and Forecast 207-2028
3.1 The Contract Biological drug API Manufacturing Services Market Performance, 2017
3.1.1 Contract Biological drug API Manufacturing Services: Forecast 2017-2028
3.2 Drivers and Restraints in the Biological Drug API Manufacturing Services Market
3.2.1 Drivers in the Biological Drug API Manufacturing Market
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biological drug API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biological drug API Services: Increased Demand

4. Biological drug API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2017-2028
4.1 Submarkets for the Biological drug API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.2 The Mammalian Cell Culture Submarket Forecast 2017-2028
4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2017-2028
4.1.4 The Microbial Fermentation Submarket
4.1.5 The Microbial Fermentation Submarket Forecast 2017-2028
4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2017-2028
4.1.6 Other APIs Expression Systems Are Still in Development
4.1.6.1 Plant-Made Pharmaceuticals
4.1.6.2 Yeast Cell Expression Systems
4.1.6.3 Insect Cell Expression Systems
4.1.6.4 Other Expression Systems Submarket Forecast 2017-2028
4.2 Chapter Summary: Positive Growth for the Market

5. Biological drug API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2017-2028
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2017-2028
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2017-2028
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2017-2028
5.3.2 Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market 2017 to 2028
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2017-2028
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2017 to 2028
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological
Products 2017-2028

6. Leading National Markets for Contract Biological drug API Manufacturing Services 2017-2028
6.1 Regional Breakdown of the World Biological drug API Manufacturing Services Market
6.1.1 US and EU Dominate Growth for Leading National Submarkets 2017-2028
6.1.2 National Revenue Shares by 2028: Emerging Market Growth
6.2 Contract Biological drug API Manufacturing in EU Market 2017-2028
6.2.1 Strong Growth for the EU Revenue Forecasts 2017-2028
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2017-2028
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2017-2028
6.2.3 US: A Market Leader in Biological drug API Manufacturing
6.2.4 Japan: A Less Mature Contract Manufacturing Market
6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2017 - 2028
6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2017-2028
6.2.5.3 China is Poised for Growth: Forecast for 2017-2028
6.2.5.4 India Offers a Lower-Cost Advantage for Biological drug API Manufacturing Services: Forecast 2017-2028
6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.2.5.6 Russian Biological drug API Manufacturing Services Forecast: 2017-2028
6.2.5.7 Brazilian Biological drug API Manufacturing Services Forecast: 2017-2028
6.2.6 South Korea: Market Forecast, 2017-2028
6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
6.2.7 Singapore: Market Forecast, 2017-2028
6.3 Summary of Chapter: Outlook for Leading National Submarkets 2017-2028

7. Leading CMOs in the Biological drug API Manufacturing Services Market
7.1 Four Companies Led the Market in 2017
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2017-2028
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
7.6 DSM Biologics: Strategically Increasing Capacity
7.7 Lonza Has the Largest Worldwide Cell Culture Capacity
7.7.1 Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
7.8 Other Market Players of Interest in 2017
7.8.1 Samsung BioLogics: Focusing on Biosimilars
7.8.2 Cytovance Biologics: Plans to Expand
7.8.3 Fujifilm Diosynth Biotechnologies
7.8.3.1 Facility and Service Expansion for the Future
7.9 Leading Biopharma Companies Operate CMO Divisions
7.9.1 AbbVie Contract Manufacturing: Strength through Acquisition
7.9.2 GSK Biopharmaceuticals
7.9.3 Sandoz: Expertise in Biologics and Biosimilars
7.9.4 Rentschler Biotechnologie: Recent Expansions
7.10 Teva: A Future Player in the Biologics Market
7.11 Catalent Offers a New Platform through Partnership
7.12 Chapter Summary: Leading Companies 2017-2028

8. Biological drug API Manufacturing Services Market Industry Trends 2017-2028: Qualitative Analysis
8.1 SWOT Analysis: Strengths and Weaknesses of the Biological drug API Manufacturing Services Market 2017
8.1.1 Biopharmaceutical Demand for Outsourcing is increasing
8.1.2 A Fragmented Market with a Costly and Difficult Manufacturing Process
8.2 Opportunities for the Biological drug API Manufacturing Services Market 2017-2028
8.3 Threats for the Biological drug API Manufacturing Services Market 2017-2028
8.4 STEP Analysis of the Biological drug API Manufacturing Services Market
8.4.1 Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
8.4.2 Technological Factors: Advances Will Drive Growth
8.4.2.1 Single-Use Technology: A Vital Trend for the Future
8.4.3 Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
8.4.4 Political Factors: Regulatory Requirements Need to Be Met
8.5 Trends in Biological Drug Development 2017-2028
8.5.1 Biosimilars Will Be an Important Opportunity for CMOs
8.5.2 CMOs are investing in Next-Generation Antibody Development
8.5.3 Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
8.5.4 Outlook for Single-Use Technologies in Biological drug API Manufacturing 2017-2028
8.5.5 Outsourcing Trends for Biological drug API Manufacturing 2017-2028
8.5.5.1 Biopharma Companies Continue to Invest in In-House Facilities
8.5.5.2 Off-shoring Biological drug API Manufacturing to Emerging Markets: Not a Trend for this Decade?
8.5.5.3 Overcapacity is a Risk for the Biotech CMO Industry
8.5.5.4 Future Trends: Strategic Partnering
8.5.5.5 Alternative Expression Methods
8.6 Regulations and Effects on the Biological drug API Manufacturing Services Industry
8.6.1 Effect on the Emerging Biological drug API Manufacturing Services Market 2017-2028
8.6.2 Regulations in Other Countries in the Biological drug API Market
8.7 Chapter Summary: Industry Trends for Contract Biological drug API Manufacturing to 2028

9. Conclusions
9.1 The Contract Biological drug API Manufacturing Services Market
9.2 Outlook for the Biological drug API Manufacturing Services Market
9.2.1 Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biological drug API Manufacturing
9.2.2 The US and EU Markets Lead for the Global Biological drug API Manufacturing Services Market in 2017
9.2.3 Single-Use Technology Will Become Indispensable for Success in the Market
9.3 Growth in the Market 2017-2028
9.3.1 The Future of the Biological drug API Manufacturing Services Marketplace
Appendices
Glossary
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2017
Table 3.1 Contract Biological drug API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Table 4.1 Contract Biological drug API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR (%), CAGR (%), 2017-2028
Table 4.2 ADC Pipeline 2017
Table 4.3 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Table 4.4 Selected CMOs Investing in Biological API Manufacturing Capacity, 2017
Table 4.5 Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Table 4.6 Other Expression Systems Submarket Two-Year Forecast Revenues ($bn), AGR (%), 2017-2028
Table 5.1 Top Ten Best-Selling Drugs in 2017: Revenue ($bn)
Table 5.2 Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2017-2028
Table 5.3 Monoclonal Antibody Types and Sources
Table 5.4 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 5.5 The Four Classes of Next- Generation Antibody Therapies
Table 5.6 Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2017-2028
Table 5.7 Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Table 5.8 Interferon Therapies Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 5.9 Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 5.10 Selected Long-Acting Growth Hormones in Development, 2017
Table 6.1 Contract Biological drug API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2017
Table 6.2 Contract Biological drug API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.3 Contract Biological drug API Manufacturing Market: National Revenue Two Year Shares (%), 2017-2028
Table 6.4 EU and Switzerland Contract Biological drug API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2017-2028
Table 6.5 EU and Switzerland Contract Biological drug API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2017
Table 6.6 Germany Contract Biological drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2017-2028
Table 6.7 UK Contract Biological drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2017-2028
Table 6.8 France Contract Biological drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2017-2028
Table 6.9 Switzerland Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.10 Spain Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2017-2028
Table 6.11 Italian Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.12 US Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.13 Japanese Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.14 Contract Biological drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.15 BRIC Markets: API Revenues ($bn) and Market Shares (%), 2017
Table 6.16 Chinese Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.17 India Contract Biological drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2017-2028
Table 6.18 Russia Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.19 Brazilian Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.20 South Korean Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 6.21 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2015
Table 6.22 Singaporean Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Table 7.1 Leading Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2017
Table 7.2 Selected Other Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2017
Table 7.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2017
Table 7.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2014-2016
Table 7.5 Celltrion: Revenue ($bn), CAGR (%), AGR (%), 2015-2017
Table 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), CAGR (%), AGR (%), 2013-2014
Table 7.7 Sandoz Biosimilar Pipelines: Selected Biosimilars, 2017
Table 8.1 Contract Biological drug API Manufacturing Market: Strengths and Weaknesses, 2017
Table 8.2 Contract Biological drug API Manufacturing Market: Opportunities and Threats, 2017-2028
Table 8.3 Biological drug API Manufacturing Services Market: STEP Analysis, 2017
Table 8.4 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2017
Table 8.5 Approved Next-Generation Antibody Therapies, 2017
Table 9.1 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2018, 2020, 2022, 2024, 2026 and 2028
Table 9.2 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2018, 2020, 2022, 2024, 2026 and 2028

List of Figures
Figure 1.1 Biological Drug API Manufacturing Services Submarkets 2017
Figure 2.1 Steps for Biological Drug Manufacturing, 2017
Figure 2.2 Contract API Manufacturing: Market Shares by Sector (%), 2017
Figure 2.3 Future Trends in the Biological drug API Manufacturing Market, 2017-2028
Figure 3.1 Contract Biological drug API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 3.2 Contract Biological drug API Manufacturing: Market Drivers, 2017-2028
Figure 3.3 Contract Biological drug API Manufacturing: Market Restraints, 2017-2028
Figure 4.1 Contract Biological drug API Manufacturing: Market Shares (%) by Sector, 2017
Figure 4.2 Mammalian Cell Culture Submarket Forecast, Revenue ($bn), AGR (%), 2017-2028
Figure 4.3 Mammalian Cell Culture Submarket: Drivers and Restraints, 2017-2028
Figure 4.4 Microbial Fermentation Submarket Forecast($bn), AGR (%), 2017-2028
Figure 4.5 Microbial Fermentation Submarket: Drivers and Restraints, 2017
Figure 4.6 Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Figure 5.1 Leading Contract API Biological Drug by Sector, 2017
Figure 5.2 Monoclonal Antibody Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2028
Figure 5.3 Vaccines Market: Contract API Revenues Forecast ($bn), AGR (%) 2017-2028
Figure 5.4 Comparison between biomanufacturing platforms for Vaccine production: VLP
Figure 5.5 Insulin Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2028
Figure 5.6 Interferon Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2028
Figure 5.7 Growth Hormones Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2028
Figure 6.1 Contract Biological drug API Manufacturing: Market Shares by Region (%), 2017
Figure 6.2 Contract Biological drug API Manufacturing: Market Shares by Region (%) 2020
Figure 6.3 Contract Biological drug API Manufacturing: Market Shares by Region (%) 2028
Figure 6.4 EU and Switzerland Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.5 EU Contract Biological drug API Manufacturing: Leading National Revenue Shares (%), 2017
Figure 6.6 Germany Contract Biological drug API Manufacturing Revenue Forecast ($bn), 2017-2028
Figure 6.7 UK Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.8 France Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.9 Switzerland Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.10 Spanish Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.11 Italian Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.12 US Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.13 Japanese Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.14 Contract Biological drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2017 -2028
Figure 6.15 Biologics Market: BRIC Revenue Shares (%), 2017
Figure 6.16 Chinese Contract Biological drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2028
Figure 6.17 India Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.18 Russia Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.19 Brazilian Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.20 South Korean Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 6.21 Singaporean Contract Biological drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2028
Figure 7.1 Leading Biological drug API CMOs: Mammalian Cell Culture Manufacturing Scale, 2017
Figure 7.2 Leading Biological drug API CMOs: Microbial Fermentation Manufacturing Scale, 2017
Figure 7.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2014-2016
Figure 7.4 Celltrion: Revenue ($bn), 2015-2017
Figure 7.5 DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2015
Figure 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2013-2017
Figure 9.1 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2017 - 2028
Figure 9.2 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2018, 2020, 2022, 2024, 2026 and 2028

発刊日

2018/07/06

体裁

PDF / 209ページ

販売価格

2,699GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

創薬一般 / アウトソーシング

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE